Here are my notes from concall…plz add if missed something
Showing Q4 sales. We had dropped share from 9 to 4%. Abilify continues to be big. There will be lot more erosion due to new entrant. It is marketed through a partner.
Ex-abilify US has also grown
Abilify ODT- Small product without competition. We are doing a good job. Gradually increasing market share
- Better margins
- Gives control over opportunity, supply chain
Its not just about gaining market share. Multiple factors- eg How confident are you of supplies? Sometimes you may make more money with smaller share (?)
Own front end came and did good job in other launches. Happy with progress. double digit share in some pdts.
Settled with erstwhile partner to launch from own front end. One time cost in other expense. Cant share details due to confidentiality agreement. Wait for Q2 to get clarity. All shifting of old products is completed.
Pricing pressure- Generally, FDA giving faster approvals. With new launches, there will be pricing pressure. This is across the board whether you are a small or large player.
Launched one product Lamotrigine
Pristiq not launched
Warfarin- Co-developed product. Lack of clarity from FDA and marketing. Not counting too much on it.
Benicar- Oct 2016 settlement? Cant comment
R&D spend- 400-450cr full yr so next Qs will be higher. Some variations may happen due to nature of work eg clinical trials etc.
Filing rates have been lower than what we want. Ramp up from H2.
Everyone talking of complex generics, onco, injectibles but it all depends on execution.
6-8 launches for the year. Litigation products you can look up.
31 products pending approval (6 are 2-3 yrs, 4 are 1-2 yrs, 9 are 0-1 yrs). 40% are either Para 4 or FTF.
JV with orbicular-Will develop basket of derma pdts. Facility not ready but development is in advanced stage.
FY18 could be same or higher R&D expense.
Capex- about 500cr this year. 1000 cr over 2-2.5 years
Onco injectibles facility ready by end of this year. Filings will come H2 next yr onwards.
General injectibles- end of next year.
Derma also end of next year.
Depreciation- 20cr per Q
Pre-R&D EBITDA will continue to improve on base business. Post R&D there will be a pressure.